After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
We have now added a new section called the "Assay History List" to the "At A Gla...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
CTS will be transitioning to a new sFTP server for clients who send test request and/or receive...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...